MedPath
HSA Approval

UNIFLEX CREAM 0.025% w/w

SIN07620P

UNIFLEX CREAM 0.025% w/w

UNIFLEX CREAM 0.025% w/w

January 25, 1994

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

CREAM

**DOSAGE AND ADMINISTRATION** For external use only. Apply sparingly onto the affected area 2 to 3 times a day. When a favourable response is obtained, reduce application gradually and eventually discontinue.

TOPICAL

Medical Information

**INDICATIONS** For the relief of inflammatory manifestations of corticosteroid-responsive dermatoses such as in eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, some form of psoriasis and intertrigo.

**CONTRAINDICATIONS** Unless under medical supervision, **Uniflex** should not be used for rosacea or on areas around the mouth. **Uniflex** should not be used for acne, viral skin infections e.g. herpes simplex (cold sores) and chicken pox; fungal infections e.g. candidiasis; bacterial infections; in patients with a history of sensitivity to any of its components. Do not use in children under one year of age, including dermatitis and napkin eruptions.

D07AC01

betamethasone

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

BETAMETHASONE 17-VALERATE EQV BETAMETHASONE

0.025% w/w

Betamethasone

Documents

Package Inserts

Uniflex PI.pdf

Approved: November 25, 2020

Download
© Copyright 2025. All Rights Reserved by MedPath